Radiation via Monoclonal Antibodies: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
VisualWikitext
(Created page with "<includeonly> {| class="wikitable" |- ! Property !! Information |- | Drug Name || Radiation via Monoclonal Antibodies |- | FDA Approval || Under research, not yet FDA-approved for general use |- | Used for || Glioblastoma (GBM) and potentially other high-grade glioma tumors |- | Clinical Trial Phase || Various phases, with some treatments in early clinical trials |- | Common Side Effects || Side effects vary depending on the specific monoclonal antibody and radioactive c...")
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
<includeonly>
{{TreatmentInfo
{| class="wikitable"
|drug_name=Radiation via Monoclonal Antibodies
|-
|FDA_approval=No
! Property !! Information
|used_for=Glioblastoma and potentially other high-grade glioma tumors
|-
|clinical_trial_phase=Early to mid-stage clinical trials
| Drug Name || Radiation via Monoclonal Antibodies
|common_side_effects=Varies; can include fatigue, headache, localized reactions at infusion site
|-
|OS_without=Standard treatments for GBM typically result in a median overall survival of 14-17 months
| FDA Approval || Under research, not yet FDA-approved for general use
|OS_with=Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts
|-
|PFS_without=Median progression-free survival with standard treatments is about 6-9 months for GBM
| Used for || Glioblastoma (GBM) and potentially other high-grade glioma tumors
|PFS_with=Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments
|-
|usefulness_rating=3
| Clinical Trial Phase || Various phases, with some treatments in early clinical trials
|usefulness_explanation=Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment
|-
|treatment_category=Radiation
| Common Side Effects || Side effects vary depending on the specific monoclonal antibody and radioactive compound used; potential side effects include fatigue, headache, and localized reactions at the infusion site
|toxicity_level=3
|-
|toxicity_explanation=Potential risks are present and may be comparable to or slightly less than traditional treatments, with concerns about toxicity under investigation
| OS without || Standard treatments for GBM usually result in a median overall survival of approximately 14-17 months【8†source】
|book_text=Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations.
|-
}}
| OS with || Early clinical trials have shown varied results; for example, median survival times of 56 weeks for recurrent GBM tumors to up to 24.9 months in some patient cohorts【7†source】【8†source】
|-
| PFS without || Standard treatments offer a median progression-free survival of 6-9 months for GBM
|-
| PFS with || Studies report mean progression-free survival of up to 17.2 months in some treatments compared to 4-10 months for other procedures【7†source】
|-
| Usefulness Rating || 3 (Potentially promising but requires more research for a definitive assessment)
|-
| Usefulness Explanation || Potential to provide targeted radiation to tumor cells while sparing normal brain tissue, possibly reducing side effects and improving outcomes
|-
| Toxicity Level || 3 (Variable; potential risks are present but appear to be comparable to or slightly less than traditional treatments)
|-
| Toxicity Explanation|| While generally considered to produce less radiation necrosis than traditional radiation therapies, the risk of toxicity remains a concern and is under investigation
|-
| Notes || This approach involves attaching radioactive iodine-131 to monoclonal antibodies that target specific antigens on tumor cells, offering a targeted radiation therapy. Currently, Duke University has been a primary treatment center for this procedure. Challenges include the blood-brain barrier and the immunosuppressive tumor microenvironment.
|-
| Links || *Not specified due to the general nature of the summary and reliance on academic and clinical research articles for information.
<div style="margin-top:20px; padding:10px; background-color:#e0e0e0; color:black; border:1px solid #ccc;">
'''Original Text:'''
Not specified; information synthesized from recent research articles and clinical trial reports on the use of monoclonal antibodies for radiation delivery in GBM treatment.
</div>
[[Category:Glioblastoma Treatments]]
</includeonly>

Latest revision as of 20:12, 20 November 2024

Property Information
Drug Name Radiation via Monoclonal Antibodies
FDA Approval No
Used for Glioblastoma and potentially other high-grade glioma tumors
Clinical Trial Phase Early to mid-stage clinical trials
Clinical Trial Explanation Not specified
Common Side Effects Varies; can include fatigue, headache, localized reactions at infusion site
OS without Standard treatments for GBM typically result in a median overall survival of 14-17 months
OS with Early trials show median survival times from 56 weeks for recurrent GBM to up to 24.9 months in certain cohorts
PFS without Median progression-free survival with standard treatments is about 6-9 months for GBM
PFS with Some studies report mean progression-free survival up to 17.2 months, compared to 4-10 months for other treatments
Usefulness Rating 3
Usefulness Explanation Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment
Toxicity Level 3
Toxicity Explanation Potential risks are present and may be comparable to or slightly less than traditional treatments, with concerns about toxicity under investigation



From Ben Williams Book: Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations.Property "Has original text" (as page type) with input value "Radiation therapy via monoclonal antibodies introduces a targeted approach to delivering radiation to glioblastoma cells. This method involves attaching radioactive isotopes, such as iodine-131, to monoclonal antibodies that target specific antigens present on tumor cells but not on normal brain cells. The approach aims to maximize the therapeutic impact on the tumor while minimizing exposure and damage to surrounding healthy brain tissue. Duke University has been a pioneer in applying this technique. The major challenges include overcoming the blood-brain barrier and navigating the immunosuppressive tumor microenvironment. Early clinical trials have shown promising outcomes, with certain patient cohorts experiencing extended median survival times. However, the effectiveness and safety of this treatment are still under active investigation, highlighting the need for ongoing research and clinical trials to fully understand its potential and limitations." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.

Loading comments...
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Radiation_via_Monoclonal_Antibodies&oldid=94094"